# A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

> **NCT00350090** · PHASE3 · TERMINATED · sponsor: **Ortho Biotech Products, L.P.** · enrollment: 98 (actual)

## Conditions studied

- Anemia
- Neoplasms

## Interventions

- **DRUG:** Epoetin Alfa

## Key facts

- **NCT ID:** NCT00350090
- **Lead sponsor:** Ortho Biotech Products, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** This study was stopped early due to slow enrollment.
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350090, "A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00350090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*